Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25484250,absorption half-life,"For subcutaneous injection, absorption half-life and peak plasma concentration of butorphanol were 0.10 ± 0.07 h and 88 ± 37.4 ng/mL (mean ± SD), respectively.",Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),h,0.10,2396,DB00611,Butorphanol
,25484250,peak plasma concentration,"For subcutaneous injection, absorption half-life and peak plasma concentration of butorphanol were 0.10 ± 0.07 h and 88 ± 37.4 ng/mL (mean ± SD), respectively.",Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),[ng] / [ml],88,2397,DB00611,Butorphanol
,25484250,Bioavailability,Bioavailability was 87%.,Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),%,87,2398,DB00611,Butorphanol
,25484250,steady-state volume of distribution,"After intravenous injection, mean ± SD butorphanol steady-state volume of distribution and clearance was 1.2 ± 0.96 L/kg and 0.65 ± 0.20 L/kg/h, respectively.",Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),[l] / [kg],1.2,2399,DB00611,Butorphanol
,25484250,clearance,"After intravenous injection, mean ± SD butorphanol steady-state volume of distribution and clearance was 1.2 ± 0.96 L/kg and 0.65 ± 0.20 L/kg/h, respectively.",Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),[l] / [h·kg],0.65,2400,DB00611,Butorphanol
,25484250,Terminal half-lives,Terminal half-lives for butorphanol were 2.31 ± 1.74 h and 5.29 ± 1.72 h after intravenous and subcutaneous administrations.,Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),h,2.31,2401,DB00611,Butorphanol
,25484250,Terminal half-lives,Terminal half-lives for butorphanol were 2.31 ± 1.74 h and 5.29 ± 1.72 h after intravenous and subcutaneous administrations.,Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484250/),h,5.29,2402,DB00611,Butorphanol
,7762853,clearance,"The clearance of mirfentanil was high (5.8-7.2 L/min), and the volume of distribution large (247-348 L).",Pharmacokinetic/dynamic assessment in drug development: application to the investigational opioid mirfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7762853/),[l] / [min],5.8-7.2,6056,DB00611,Butorphanol
,7762853,volume of distribution,"The clearance of mirfentanil was high (5.8-7.2 L/min), and the volume of distribution large (247-348 L).",Pharmacokinetic/dynamic assessment in drug development: application to the investigational opioid mirfentanil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7762853/),l,247-348,6057,DB00611,Butorphanol
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00611,Butorphanol
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00611,Butorphanol
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00611,Butorphanol
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00611,Butorphanol
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00611,Butorphanol
,8157043,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) for the transnasal treatment with and without pretreatment of oxymetazoline were 1.61 and 3.01 ng.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),ng,1.61,16499,DB00611,Butorphanol
,8157043,maximum concentrations (Cmax),The mean maximum concentrations (Cmax) for the transnasal treatment with and without pretreatment of oxymetazoline were 1.61 and 3.01 ng.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),ng,3.01,16500,DB00611,Butorphanol
,8157043,mean absorption times (MAT),The corresponding mean absorption times (MAT) were 1.34 and 0.23 h.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,1.34,16501,DB00611,Butorphanol
,8157043,mean absorption times (MAT),The corresponding mean absorption times (MAT) were 1.34 and 0.23 h.,The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,0.23,16502,DB00611,Butorphanol
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,5.95,16503,DB00611,Butorphanol
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,6.28,16504,DB00611,Butorphanol
,8157043,half-life,"The mean half-life values were 5.95, 6.28, and 5.77 h, for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),h,5.77,16505,DB00611,Butorphanol
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],11.9,16506,DB00611,Butorphanol
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],8.6,16507,DB00611,Butorphanol
,8157043,area under the plasma concentration curve (AUC),"The resulting mean area under the plasma concentration curve (AUC) values were 11.9, 8.6, and 8.07 ng.h.ml-1 for treatments A, B, and C, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[h·ng] / [ml],8.07,16508,DB00611,Butorphanol
,8157043,absolute bioavailability (f),"The estimates for absolute bioavailability (f) of transnasal butorphanol were 69% and 72% when administered with and without oxymetazoline, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,69,16509,DB00611,Butorphanol
,8157043,absolute bioavailability (f),"The estimates for absolute bioavailability (f) of transnasal butorphanol were 69% and 72% when administered with and without oxymetazoline, respectively.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,72,16510,DB00611,Butorphanol
,8157043,CLT,"The mean CLT and Vss were 121 l.h-1 and 791 l, respectively, for the intravenous treatment.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),[l] / [h],121,16511,DB00611,Butorphanol
,8157043,Vss,"The mean CLT and Vss were 121 l.h-1 and 791 l, respectively, for the intravenous treatment.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),l,791,16512,DB00611,Butorphanol
,8157043,absolute bioavailability,"Although the rate of absorption of transnasal butorphanol was affected by oxymetazoline, the absolute bioavailability in rhinitis patients (72%) was similar to that found with the pretreatment of oxymetazoline (69%) and those reported in healthy volunteers.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,72,16513,DB00611,Butorphanol
,8157043,absolute bioavailability,"Although the rate of absorption of transnasal butorphanol was affected by oxymetazoline, the absolute bioavailability in rhinitis patients (72%) was similar to that found with the pretreatment of oxymetazoline (69%) and those reported in healthy volunteers.",The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8157043/),%,69,16514,DB00611,Butorphanol
,19045999,terminal half-life,"Mean+/-SD terminal half-life of butorphanol for the remaining 5 cats was 6.3+/-2.8 hours and 5.2+/-1.7 hours for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),h,6.3,24357,DB00611,Butorphanol
,19045999,terminal half-life,"Mean+/-SD terminal half-life of butorphanol for the remaining 5 cats was 6.3+/-2.8 hours and 5.2+/-1.7 hours for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),h,5.2,24358,DB00611,Butorphanol
,19045999,Peak plasma butorphanol concentrations,"Peak plasma butorphanol concentrations were 132.0 and 34.4 ng/mL for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),[ng] / [ml],132.0,24359,DB00611,Butorphanol
,19045999,Peak plasma butorphanol concentrations,"Peak plasma butorphanol concentrations were 132.0 and 34.4 ng/mL for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),[ng] / [ml],34.4,24360,DB00611,Butorphanol
,19045999,Time to maximal plasma concentration,"Time to maximal plasma concentration was 0.35 and 1.1 hours for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),h,0.35,24361,DB00611,Butorphanol
,19045999,Time to maximal plasma concentration,"Time to maximal plasma concentration was 0.35 and 1.1 hours for IM and BTM administration, respectively.",Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),h,1.1,24362,DB00611,Butorphanol
,19045999,Extent of,Extent of butorphanol absorption was 37.16% following BTM application.,Pharmacokinetics of butorphanol in cats after intramuscular and buccal transmucosal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19045999/),%,37.16,24363,DB00611,Butorphanol
,26618732,Plasma concentrations,"Plasma concentrations peaked (mean, 106.4 μg/L; range, 61.8 to 133.0 μg/L) at a mean of 39.0 hours, with no evidence of sedation in any bird.",Pharmacokinetics of butorphanol delivered with an osmotic pump during a seven-day period in common peafowl (Pavo cristatus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26618732/),[μg] / [l],106.4,38714,DB00611,Butorphanol
,26618732,half-life,"After pump removal, butorphanol was rapidly eliminated (half-life, 1.45 hours; range, 1.31 to 1.64 hours; n = 5).",Pharmacokinetics of butorphanol delivered with an osmotic pump during a seven-day period in common peafowl (Pavo cristatus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26618732/),h,1.45,38715,DB00611,Butorphanol
,26618732,clearance per fraction of dose absorbed,"Mean clearance per fraction of dose absorbed was 2.89 L/kg/h (range, 2.00 to 5.55 L/kg/h).",Pharmacokinetics of butorphanol delivered with an osmotic pump during a seven-day period in common peafowl (Pavo cristatus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26618732/),[l] / [h·kg],2.89,38716,DB00611,Butorphanol
,32012314,clearance,The intravenous pharmacokinetics of butorphanol dosed individually compared with co-administration with detomidine had approximately a twofold larger clearance (646 ± 137 vs.,The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,646,42198,DB00611,Butorphanol
,32012314,terminal half-life,380 ± 86 ml hr-1 kg-1 ) but similar terminal half-life (5.21 ± 1.56 vs. 5.43 ± 0.44 hr).,The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,5.21,42199,DB00611,Butorphanol
,32012314,terminal half-life,380 ± 86 ml hr-1 kg-1 ) but similar terminal half-life (5.21 ± 1.56 vs. 5.43 ± 0.44 hr).,The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,5.43,42200,DB00611,Butorphanol
,32012314,P,"Pseudo-steady-state urine to plasma butorphanol concentration ratios were 730 and 560, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,730,42201,DB00611,Butorphanol
,32012314,P,"Pseudo-steady-state urine to plasma butorphanol concentration ratios were 730 and 560, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,560,42202,DB00611,Butorphanol
,32012314,concentration ratios,"Pseudo-steady-state urine to plasma butorphanol concentration ratios were 730 and 560, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,730,42203,DB00611,Butorphanol
,32012314,concentration ratios,"Pseudo-steady-state urine to plasma butorphanol concentration ratios were 730 and 560, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,560,42204,DB00611,Butorphanol
,32012314,clearance,"The intravenous pharmacokinetics of detomidine dosed as a single administration compared with co-administration with butorphanol had similar clearance (3,278 ± 1,412 vs. 2,519 ± 630 ml hr-1 kg-1 ) but a slightly shorter terminal half-life (0.57 ± 0.06 vs. 0.70 ± 0.11 hr).",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),[ml] / [h·kg],"3,278",42205,DB00611,Butorphanol
,32012314,clearance,"The intravenous pharmacokinetics of detomidine dosed as a single administration compared with co-administration with butorphanol had similar clearance (3,278 ± 1,412 vs. 2,519 ± 630 ml hr-1 kg-1 ) but a slightly shorter terminal half-life (0.57 ± 0.06 vs. 0.70 ± 0.11 hr).",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),[ml] / [h·kg],"2,519",42206,DB00611,Butorphanol
,32012314,terminal half-life,"The intravenous pharmacokinetics of detomidine dosed as a single administration compared with co-administration with butorphanol had similar clearance (3,278 ± 1,412 vs. 2,519 ± 630 ml hr-1 kg-1 ) but a slightly shorter terminal half-life (0.57 ± 0.06 vs. 0.70 ± 0.11 hr).",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,0.57,42207,DB00611,Butorphanol
,32012314,terminal half-life,"The intravenous pharmacokinetics of detomidine dosed as a single administration compared with co-administration with butorphanol had similar clearance (3,278 ± 1,412 vs. 2,519 ± 630 ml hr-1 kg-1 ) but a slightly shorter terminal half-life (0.57 ± 0.06 vs. 0.70 ± 0.11 hr).",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,0.70,42208,DB00611,Butorphanol
,32012314,concentration ratios,"Pseudo-steady-state urine to plasma detomidine concentration ratios are 4 and 8, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,4,42209,DB00611,Butorphanol
,32012314,concentration ratios,"Pseudo-steady-state urine to plasma detomidine concentration ratios are 4 and 8, respectively.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),,8,42210,DB00611,Butorphanol
,32012314,Detection times,"Detection times of 72 and 48 hr are recommended for the control of butorphanol and detomidine, respectively, in horseracing and equestrian competitions.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,72,42211,DB00611,Butorphanol
,32012314,Detection times,"Detection times of 72 and 48 hr are recommended for the control of butorphanol and detomidine, respectively, in horseracing and equestrian competitions.",The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32012314/),h,48,42212,DB00611,Butorphanol
,7988625,systemic availability,"The mean systemic availability of transnasal butorphanol was about 70%, except for the elderly women (48%).",The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988625/),%,70,43251,DB00611,Butorphanol
,7988625,systemic availability,"The mean systemic availability of transnasal butorphanol was about 70%, except for the elderly women (48%).",The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988625/),%,48,43252,DB00611,Butorphanol
,20945638,Cmax,"The mean Cmax after i.m. administration was 7.9 ng/ml, with a corresponding Tmax, of 40 min and t(1/3), of 7.1 h.",Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),[ng] / [ml],7.9,51297,DB00611,Butorphanol
,20945638,Tmax,"The mean Cmax after i.m. administration was 7.9 ng/ml, with a corresponding Tmax, of 40 min and t(1/3), of 7.1 h.",Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),min,40,51298,DB00611,Butorphanol
,20945638,t(1/3),"The mean Cmax after i.m. administration was 7.9 ng/ml, with a corresponding Tmax, of 40 min and t(1/3), of 7.1 h.",Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),h,7.1,51299,DB00611,Butorphanol
,20945638,Vd(ss),"After i.v. administration, the mean Vd(ss) was 1.4 L/kg and the mean Cl(p) was 0.26 L/kg/h.",Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),[l] / [kg],1.4,51300,DB00611,Butorphanol
,20945638,Cl(p),"After i.v. administration, the mean Vd(ss) was 1.4 L/kg and the mean Cl(p) was 0.26 L/kg/h.",Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),[l] / [h·kg],0.26,51301,DB00611,Butorphanol
,20945638,bioavailability,Mean i.m. bioavailability was 37%.,Pharmacokinetics and intramuscular bioavailability of a single dose of butorphanol in Asian elephants (Elephas maximus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20945638/),%,37,51302,DB00611,Butorphanol
,10493642,Tmax,"Tmax was 31 mins in the control group, and this increased significantly (P<.05) after sedation.",The effect of sedation on gastric emptying of a liquid marker in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10493642/),min,31,58609,DB00611,Butorphanol
,11697372,peak plasma concentrations,"Extrapolated peak plasma concentrations after i.v. and i.m. administration were 94.8 +/- 53.1 and 34.3 +/- 11.6 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),[ng] / [ml],94.8,62113,DB00611,Butorphanol
,11697372,peak plasma concentrations,"Extrapolated peak plasma concentrations after i.v. and i.m. administration were 94.8 +/- 53.1 and 34.3 +/- 11.6 ng/ml, respectively.",Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),[ng] / [ml],34.3,62114,DB00611,Butorphanol
,11697372,Volume of distribution at steady state,Volume of distribution at steady state after i.v. administration was 0.822 +/- 0.329 L/kg per minute and systemic clearance was 0.050 +/- 0.014 L/kg per minute.,Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),[l] / [kg·min],0.822,62115,DB00611,Butorphanol
,11697372,systemic clearance,Volume of distribution at steady state after i.v. administration was 0.822 +/- 0.329 L/kg per minute and systemic clearance was 0.050 +/- 0.014 L/kg per minute.,Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),[l] / [kg·min],0.050,62116,DB00611,Butorphanol
,11697372,elimination half-life,"Slope of the elimination phase was significantly different, and elimination half-life was significantly shorter after i.v. (15.9 +/- 9.1 minutes) versus i.m. (66.8 +/- 13.5 minutes) administration.",Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),min,15.9,62117,DB00611,Butorphanol
,11697372,elimination half-life,"Slope of the elimination phase was significantly different, and elimination half-life was significantly shorter after i.v. (15.9 +/- 9.1 minutes) versus i.m. (66.8 +/- 13.5 minutes) administration.",Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),min,66.8,62118,DB00611,Butorphanol
,11697372,Bioavailability,Bioavailability was 110 +/- 49% after i.m. administration.,Pharmacokinetics and pharmacodynamics of butorphanol in llamas after intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697372/),%,110,62119,DB00611,Butorphanol
,8866454,Maximum concentration,"Maximum concentration of butorphanol and time to obtain this concentration were 42.28 ng/mL at 13.88 min in blood, and 18.03 ng/mL at 30 min in CSF.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[ng] / [ml],42.28,67698,DB00611,Butorphanol
,8866454,Volume of distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [kg],4.39,67699,DB00611,Butorphanol
,8866454,clearance,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [h·kg],2.02,67700,DB00611,Butorphanol
,8866454,clearance,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,16.5,67701,DB00611,Butorphanol
,8866454,distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),[l] / [h·kg],2.02,67702,DB00611,Butorphanol
,8866454,distribution,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,16.5,67703,DB00611,Butorphanol
,8866454,elimination half-lives,"Volume of distribution, clearance, mean distribution and elimination half-lives were respectively 4.39 L/kg, 2.02 L/h.kg, 16.5 min and 189.1 min.",Pharmacokinetics of epidural butorphanol in isoflurane-anaesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866454/),min,189.1,67704,DB00611,Butorphanol
,7391944,peak serum concentration,The mean peak serum concentration was 29 ng/ml at mean times of 28 min after subcutaneous administration and 40 min after intramuscular administration.,Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391944/),[ng] / [ml],29,68885,DB00611,Butorphanol
,7391944,serum half-life,"The serum half-life was 1.62 hr, and the serum clearance was 3.45 liters/kg/hr.",Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391944/),h,1.62,68886,DB00611,Butorphanol
,7391944,serum clearance,"The serum half-life was 1.62 hr, and the serum clearance was 3.45 liters/kg/hr.",Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391944/),[l] / [h·kg],3.45,68887,DB00611,Butorphanol
,7391944,apparent volume of distribution,The apparent volume of distribution of butorphanol was 7.96 liters/kg.,Pharmacokinetics of subcutaneous and intramuscular butorphanol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391944/),[l] / [kg],7.96,68888,DB00611,Butorphanol
,22339417,systemic clearance,"Mean±SD systemic clearance, steady-state volume of distribution, and terminal elimination half-life were 11.5±2.5 mL/min/kg, 1.4±0.3 L/kg, and 5.9±1.5 h, respectively.",Pharmacokinetics and pharmacodynamics of butorphanol following intravenous administration to the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339417/),[ml] / [kg·min],11.5,84748,DB00611,Butorphanol
,22339417,steady-state volume of distribution,"Mean±SD systemic clearance, steady-state volume of distribution, and terminal elimination half-life were 11.5±2.5 mL/min/kg, 1.4±0.3 L/kg, and 5.9±1.5 h, respectively.",Pharmacokinetics and pharmacodynamics of butorphanol following intravenous administration to the horse. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339417/),[l] / [kg],1.4,84749,DB00611,Butorphanol
,22339417,terminal elimination half-life,"Mean±SD systemic clearance, steady-state volume of distribution, and terminal elimination half-life were 11.5±2.5 mL/min/kg, 1.4±0.3 L/kg, and 5.9±1.5 h, respectively.",Pharmacokinetics and pharmacodynamics of butorphanol following intravenous administration to the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339417/),h,5.9,84750,DB00611,Butorphanol
,9113342,accumulation index,Steady state levels of butorphanol were attained within 3 days (d) of q6h dosing and the accumulation index was 1.2 for butorphanol.,The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113342/),,1.2,86318,DB00611,Butorphanol
,9113342,t1/2,"Due to a relatively long t1/2 of 15 h of HO-B compared to the dosing interval (q6h), the accumulation index was 6.0 for this metabolite.",The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113342/),h,15,86319,DB00611,Butorphanol
,9113342,accumulation index,"Due to a relatively long t1/2 of 15 h of HO-B compared to the dosing interval (q6h), the accumulation index was 6.0 for this metabolite.",The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9113342/),,6.0,86320,DB00611,Butorphanol
,11212025,Elimination half-life,Elimination half-life of butorphanol was brief (44.37 minutes).,Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212025/),min,44.37,99724,DB00611,Butorphanol
,11212025,plasma concentration,"Adverse gastrointestinal tract effects were less apparent during continuous 24-hour infusion of butorphanol at a dosage that resulted in a mean plasma concentration of 29 ng/ml, compared with effects after a single IV injection.",Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11212025/),ng,29,99725,DB00611,Butorphanol
<,22216718,bioavailability,"In contrast, oral administration resulted in low bioavailability (< 10%), thus precluding the use of this route of administration for clinical purposes.","Pharmacokinetics of butorphanol after intravenous, intramuscular, and oral administration in Hispaniolan Amazon parrots (Amazona ventralis). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22216718/),%,10,100046,DB00611,Butorphanol
,21628341,terminal half-life (T(1/2.z)),"With non-compartmental analysis, the terminal half-life (T(1/2.z)) was 71.3 minutes, clearance was 67.6 ml/minute/kg and the apparent volume of distribution was 6.9 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),min,71.3,107835,DB00611,Butorphanol
,21628341,clearance,"With non-compartmental analysis, the terminal half-life (T(1/2.z)) was 71.3 minutes, clearance was 67.6 ml/minute/kg and the apparent volume of distribution was 6.9 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),[ml] / [kg·min],67.6,107836,DB00611,Butorphanol
,21628341,apparent volume of distribution,"With non-compartmental analysis, the terminal half-life (T(1/2.z)) was 71.3 minutes, clearance was 67.6 ml/minute/kg and the apparent volume of distribution was 6.9 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),[l] / [kg],6.9,107837,DB00611,Butorphanol
,21628341,elimination half-life (T(1/2β)),"In this analysis, elimination half-life (T(1/2β)) was 69.3 minutes, clearance was 74.6 ml/minute/kg and volume of distribution at steady state was 5.6 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),min,69.3,107838,DB00611,Butorphanol
,21628341,clearance,"In this analysis, elimination half-life (T(1/2β)) was 69.3 minutes, clearance was 74.6 ml/minute/kg and volume of distribution at steady state was 5.6 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),[ml] / [kg·min],74.6,107839,DB00611,Butorphanol
,21628341,volume of distribution at steady state,"In this analysis, elimination half-life (T(1/2β)) was 69.3 minutes, clearance was 74.6 ml/minute/kg and volume of distribution at steady state was 5.6 l/kg.",Pharmacokinetics of butorphanol in broiler chickens. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),[l] / [kg],5.6,107840,DB00611,Butorphanol
,21628341,k(21),"The micro rate constants k(21), k(12) and k(10) were 0.034, 0.050 and 0.029, respectively.",Pharmacokinetics of butorphanol in broiler chickens. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),,0.034,107841,DB00611,Butorphanol
,21628341,k(12),"The micro rate constants k(21), k(12) and k(10) were 0.034, 0.050 and 0.029, respectively.",Pharmacokinetics of butorphanol in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),,0.050,107842,DB00611,Butorphanol
,21628341,k(12),"The micro rate constants k(21), k(12) and k(10) were 0.034, 0.050 and 0.029, respectively.",Pharmacokinetics of butorphanol in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),,0.029,107843,DB00611,Butorphanol
,21628341,k(10),"The micro rate constants k(21), k(12) and k(10) were 0.034, 0.050 and 0.029, respectively.",Pharmacokinetics of butorphanol in broiler chickens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21628341/),,0.029,107844,DB00611,Butorphanol
,18447789,Terminal half-lives,"Terminal half-lives of butorphanol were 0.94 +/- 0.30 hours (IVj) and 0.94 +/- 0.26 hours (IM) for RTHs and 1.79 +/- 1.36 hours (IVj), 1.84 +/- 1.56 hours (IM), and 1.19 +/- 0.34 hours (IVm) for GHOs.",Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),h,0.94,109186,DB00611,Butorphanol
,18447789,Terminal half-lives,"Terminal half-lives of butorphanol were 0.94 +/- 0.30 hours (IVj) and 0.94 +/- 0.26 hours (IM) for RTHs and 1.79 +/- 1.36 hours (IVj), 1.84 +/- 1.56 hours (IM), and 1.19 +/- 0.34 hours (IVm) for GHOs.",Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),h,0.94,109187,DB00611,Butorphanol
,18447789,Terminal half-lives,"Terminal half-lives of butorphanol were 0.94 +/- 0.30 hours (IVj) and 0.94 +/- 0.26 hours (IM) for RTHs and 1.79 +/- 1.36 hours (IVj), 1.84 +/- 1.56 hours (IM), and 1.19 +/- 0.34 hours (IVm) for GHOs.",Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),h,1.79,109188,DB00611,Butorphanol
,18447789,Terminal half-lives,"Terminal half-lives of butorphanol were 0.94 +/- 0.30 hours (IVj) and 0.94 +/- 0.26 hours (IM) for RTHs and 1.79 +/- 1.36 hours (IVj), 1.84 +/- 1.56 hours (IM), and 1.19 +/- 0.34 hours (IVm) for GHOs.",Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),h,1.84,109189,DB00611,Butorphanol
,18447789,Terminal half-lives,"Terminal half-lives of butorphanol were 0.94 +/- 0.30 hours (IVj) and 0.94 +/- 0.26 hours (IM) for RTHs and 1.79 +/- 1.36 hours (IVj), 1.84 +/- 1.56 hours (IM), and 1.19 +/- 0.34 hours (IVm) for GHOs.",Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),h,1.19,109190,DB00611,Butorphanol
,18447789,Bioavailability,Bioavailability of butorphanol administered IM was 97.6 +/- 33.2% (RTHs) and 88.8 +/- 4.8% (GHOs).,Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),%,97.6,109191,DB00611,Butorphanol
,18447789,Bioavailability,Bioavailability of butorphanol administered IM was 97.6 +/- 33.2% (RTHs) and 88.8 +/- 4.8% (GHOs).,Pharmacokinetics of butorphanol tartrate in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18447789/),%,88.8,109192,DB00611,Butorphanol
,15658072,bioavailability,"Intranasal butorphanol 1 and 2 mg administered using unit dose sprayers had a mean bioavailability of approximately 80%, which is higher than the percentage reported with the commercially available multidose product (61-69%).",Bioavailability of intranasal butorphanol administered from a single-dose sprayer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15658072/),%,80,125117,DB00611,Butorphanol
,15658072,bioavailability,"Intranasal butorphanol 1 and 2 mg administered using unit dose sprayers had a mean bioavailability of approximately 80%, which is higher than the percentage reported with the commercially available multidose product (61-69%).",Bioavailability of intranasal butorphanol administered from a single-dose sprayer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15658072/),%,61-69,125118,DB00611,Butorphanol
,15658072,time to reach maximum concentration,"The absorption of intranasal butorphanol was rapid, with a median time to reach maximum concentration of 20 minutes (range, 10-60 minutes).",Bioavailability of intranasal butorphanol administered from a single-dose sprayer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15658072/),min,20,125119,DB00611,Butorphanol
,33423953,terminal half-life,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),min,44.3,130142,DB00611,Butorphanol
,33423953,volume of distribution,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[l] / [kg],0.43,130143,DB00611,Butorphanol
,33423953,plasma clearance,"The terminal half-life was 44.3 ± 18.0 minutes, volume of distribution 0.43 ± 0.12 L kg-1 and plasma clearance 7.77 ± 1.98 mL minute-1 kg-1.",Pharmacokinetics and pharmacodynamics of l-methadone in isoflurane-anaesthetized and mechanically ventilated ponies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33423953/),[ml] / [kg·min],7.77,130144,DB00611,Butorphanol
,1573703,Apparent volume of distribution,"Apparent volume of distribution was 4.178 +/- 1.145 (mean +/- SD) 1/kg, mean elimination half-life was 82 min, and clearance was 34.6 +/- 7.7 ml/min/kg.",Pharmacokinetics and milk residues of butorphanol in dairy cows after single intravenous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573703/),[1] / [kg],4.178,136424,DB00611,Butorphanol
,1573703,elimination half-life,"Apparent volume of distribution was 4.178 +/- 1.145 (mean +/- SD) 1/kg, mean elimination half-life was 82 min, and clearance was 34.6 +/- 7.7 ml/min/kg.",Pharmacokinetics and milk residues of butorphanol in dairy cows after single intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573703/),min,82,136425,DB00611,Butorphanol
,1573703,clearance,"Apparent volume of distribution was 4.178 +/- 1.145 (mean +/- SD) 1/kg, mean elimination half-life was 82 min, and clearance was 34.6 +/- 7.7 ml/min/kg.",Pharmacokinetics and milk residues of butorphanol in dairy cows after single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1573703/),[ml] / [kg·min],34.6,136426,DB00611,Butorphanol
,8735680,elimination half-life,4. The elimination half-life of butorphanol increased from 5.75 h in NOR to 10.48 h in SI.,Pharmacokinetics of butorphanol nasal spray in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735680/),h,5.75,136707,DB00611,Butorphanol
,8735680,elimination half-life,4. The elimination half-life of butorphanol increased from 5.75 h in NOR to 10.48 h in SI.,Pharmacokinetics of butorphanol nasal spray in patients with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735680/),h,10.48,136708,DB00611,Butorphanol
,17520448,transdermal fluxes,"The presence of 1% of transkarbam 12 (T12) or 5% of laurocapram (LC), respectively, in an isopropylmyristate (IPM) donor vehicle increased transdermal fluxes of butorphanol almost 2.5 times (58.1+/-5.7 microg cm-2 hr-1) or 1.5 times (36.4+/-7.0 microg cm-2 hr-1), respectively, when compared to blank donors.",In vitro studies on transdermal permeation of butorphanol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520448/),[μg] / [(cm)^2·h],58.1,144081,DB00611,Butorphanol
,17520448,transdermal fluxes,"The presence of 1% of transkarbam 12 (T12) or 5% of laurocapram (LC), respectively, in an isopropylmyristate (IPM) donor vehicle increased transdermal fluxes of butorphanol almost 2.5 times (58.1+/-5.7 microg cm-2 hr-1) or 1.5 times (36.4+/-7.0 microg cm-2 hr-1), respectively, when compared to blank donors.",In vitro studies on transdermal permeation of butorphanol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520448/),[μg] / [(cm)^2·h],36.4,144082,DB00611,Butorphanol
,17520448,flux,"Considering clinical and pharmacokinetic data on butorphanol, it is possible to expect that a transdermal preparation sized 20 cm2 and possessing flux values ranging between 5.1 and 15.3 microg cm-2 hr-1 should be sufficient to achieve effective butorphanol transdermal fluxes, namely using IPM donors containing T12.",In vitro studies on transdermal permeation of butorphanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520448/),[μg] / [(cm)^2·h],5.1 and 15.3,144083,DB00611,Butorphanol
,8330463,AUC from time zero to infinity,"The values of AUC from time zero to infinity after a single dose of 2 mg butorphanol tartrate, 10.9 ng.hr/ml, were identical to the values of AUC(0-tau) after a multiple administration of 2 mg dose, 10.4 ng.hr/ml.",Multiple-dose phase I study of transnasal butorphanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330463/),[h·ng] / [ml],10.9,161253,DB00611,Butorphanol
,8330463,AUC(0-tau),"The values of AUC from time zero to infinity after a single dose of 2 mg butorphanol tartrate, 10.9 ng.hr/ml, were identical to the values of AUC(0-tau) after a multiple administration of 2 mg dose, 10.4 ng.hr/ml.",Multiple-dose phase I study of transnasal butorphanol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330463/),[h·ng] / [ml],10.4,161254,DB00611,Butorphanol
,8330463,elimination half-life,Mean elimination half-life value was 5.45 hours.,Multiple-dose phase I study of transnasal butorphanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330463/),h,5.45,161255,DB00611,Butorphanol
,3344601,Systemic blood clearance,"Systemic blood clearance (21.29 +/- 7.18 ml/min/kg), apparent steady-state volume of distribution (9.02 +/- 2.40 liters/kg), distribution half-life (7.67 +/- 4.66 min), and the blood/plasma concentration ratio (1.21 +/- 0.36) in the elderly did not differ from those in the younger subjects.",Influence of age on the pharmacokinetics of butorphanol. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),[ml] / [kg·min],21.29,207213,DB00611,Butorphanol
,3344601,apparent steady-state volume of distribution,"Systemic blood clearance (21.29 +/- 7.18 ml/min/kg), apparent steady-state volume of distribution (9.02 +/- 2.40 liters/kg), distribution half-life (7.67 +/- 4.66 min), and the blood/plasma concentration ratio (1.21 +/- 0.36) in the elderly did not differ from those in the younger subjects.",Influence of age on the pharmacokinetics of butorphanol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),[l] / [kg],9.02,207214,DB00611,Butorphanol
,3344601,distribution half-life,"Systemic blood clearance (21.29 +/- 7.18 ml/min/kg), apparent steady-state volume of distribution (9.02 +/- 2.40 liters/kg), distribution half-life (7.67 +/- 4.66 min), and the blood/plasma concentration ratio (1.21 +/- 0.36) in the elderly did not differ from those in the younger subjects.",Influence of age on the pharmacokinetics of butorphanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),min,7.67,207215,DB00611,Butorphanol
,3344601,blood/plasma concentration ratio,"Systemic blood clearance (21.29 +/- 7.18 ml/min/kg), apparent steady-state volume of distribution (9.02 +/- 2.40 liters/kg), distribution half-life (7.67 +/- 4.66 min), and the blood/plasma concentration ratio (1.21 +/- 0.36) in the elderly did not differ from those in the younger subjects.",Influence of age on the pharmacokinetics of butorphanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),,1.21,207216,DB00611,Butorphanol
,3344601,terminal elimination half-life,"However, the terminal elimination half-life was significantly prolonged in the elderly (5.51 +/- 2.49 versus 3.67 +/- 0.52 h, p less than 0.05).",Influence of age on the pharmacokinetics of butorphanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),h,5.51,207217,DB00611,Butorphanol
,3344601,terminal elimination half-life,"However, the terminal elimination half-life was significantly prolonged in the elderly (5.51 +/- 2.49 versus 3.67 +/- 0.52 h, p less than 0.05).",Influence of age on the pharmacokinetics of butorphanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344601/),h,3.67,207218,DB00611,Butorphanol
,28404243,Volume of distribution at steady state,"Volume of distribution at steady state after IV administration of butorphanol was 1.27 ± 0.73 L kg-1, and ClTB was 0.0096 ± 0.0024 L kg-1 minute-1.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[l] / [kg],1.27,214142,DB00611,Butorphanol
,28404243,ClTB,"Volume of distribution at steady state after IV administration of butorphanol was 1.27 ± 0.73 L kg-1, and ClTB was 0.0096 ± 0.0024 L kg-1 minute-1.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[l] / [kg·min],0.0096,214143,DB00611,Butorphanol
,28404243,C0,Extrapolated C0 of butorphanol after IV administration was 146.5 ± 49.8 ng mL-1.,Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[ng] / [ml],146.5,214144,DB00611,Butorphanol
,28404243,CMAX,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),[ng] / [ml],54.98,214145,DB00611,Butorphanol
,28404243,TMAX,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),min,16.2,214146,DB00611,Butorphanol
,28404243,bioavailability,"Estimated CMAX after IM administration of butorphanol was 54.98 ± 14.60 ng mL-1, and TMAX was 16.2 ± 5.2 minutes; bioavailability was 82 ± 41%.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),%,82,214147,DB00611,Butorphanol
,28404243,Elimination half-life,"Elimination half-life of butorphanol was 1.87 ± 1.49 and 2.75 ± 1.93 hours for IV and IM administration, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,1.87,214148,DB00611,Butorphanol
,28404243,Elimination half-life,"Elimination half-life of butorphanol was 1.87 ± 1.49 and 2.75 ± 1.93 hours for IV and IM administration, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,2.75,214149,DB00611,Butorphanol
,28404243,elimination half-life,"The dose of butorphanol (0.1 mg kg-1, IV or IM) being used clinically to treat postoperative pain in goats has an elimination half-life of 1.87 and 2.75 hours, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,1.87,214150,DB00611,Butorphanol
,28404243,elimination half-life,"The dose of butorphanol (0.1 mg kg-1, IV or IM) being used clinically to treat postoperative pain in goats has an elimination half-life of 1.87 and 2.75 hours, respectively.",Pharmacokinetics and selected behavioral responses to butorphanol and its metabolites in goats following intravenous and intramuscular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28404243/),h,2.75,214151,DB00611,Butorphanol
,14986556,area under the concentration-versus-time curve (AUC) from time zero to infinity (AUC0-infinity),"Mean (coefficient of variation) values for the area under the concentration-versus-time curve (AUC) from time zero to infinity (AUC0-infinity) were 4.15 (26.4%) and 10.42 (19.6%) ng.hr/ml after single doses of 1 and 2 mg of butorphanol, respectively.",Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),[h·ng] / [ml],4.15,214769,DB00611,Butorphanol
,14986556,area under the concentration-versus-time curve (AUC) from time zero to infinity (AUC0-infinity),"Mean (coefficient of variation) values for the area under the concentration-versus-time curve (AUC) from time zero to infinity (AUC0-infinity) were 4.15 (26.4%) and 10.42 (19.6%) ng.hr/ml after single doses of 1 and 2 mg of butorphanol, respectively.",Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),[h·ng] / [ml],10.42,214770,DB00611,Butorphanol
,14986556,AUC from time zero to the dosing interval (AUC0-tau),"At steadly state, mean values for the AUC from time zero to the dosing interval (AUC0-tau) were 4.82 (40.2%) and 10.60 (22.3%) ng.hr/mL, respectively.",Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),[h·ng] / [ml],4.82,214771,DB00611,Butorphanol
,14986556,AUC from time zero to the dosing interval (AUC0-tau),"At steadly state, mean values for the AUC from time zero to the dosing interval (AUC0-tau) were 4.82 (40.2%) and 10.60 (22.3%) ng.hr/mL, respectively.",Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),[h·ng] / [ml],10.60,214772,DB00611,Butorphanol
,14986556,accumulation indices,The accumulation indices were around 2 for both the 1- and 2-mg doses.,Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),,2,214773,DB00611,Butorphanol
,14986556,time to maximum concentration,Median time to maximum concentration values ranged from 15 to 30 minutes for each treatment.,Pharmacokinetics of butorphanol tartrate administered from single-dose intranasal sprayer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14986556/),min,15 to 30,214774,DB00611,Butorphanol
,8841151,absolute transnasal bioavailability,The absolute transnasal bioavailability of butorphanol was significantly higher (approximately 20%) in patients with hepatic impairment.,The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841151/),%,20,214838,DB00611,Butorphanol
,8218955,elimination half-life,The elimination half-life of butorphanol was about 3-5 h and was independent of the route of administration.,"Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218955/),h,3-5,228363,DB00611,Butorphanol
,8218955,absolute bioavailabilities,"Mean absolute bioavailabilities of sublingual tablet and buccal disk formulation were only 19 per cent and 29 per cent, respectively, but for transnasal administration the value rose significantly, to 70 per cent.","Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218955/),%,19,228364,DB00611,Butorphanol
,8218955,absolute bioavailabilities,"Mean absolute bioavailabilities of sublingual tablet and buccal disk formulation were only 19 per cent and 29 per cent, respectively, but for transnasal administration the value rose significantly, to 70 per cent.","Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218955/),%,29,228365,DB00611,Butorphanol
,8218955,absolute bioavailabilities,"Mean absolute bioavailabilities of sublingual tablet and buccal disk formulation were only 19 per cent and 29 per cent, respectively, but for transnasal administration the value rose significantly, to 70 per cent.","Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8218955/),%,70,228366,DB00611,Butorphanol
,6105056,plasma half-life,"Butorphanol was rapidly distributed to tissues, had a plasma half-life of about 3 hr, and was extensively metabolized prior to elimination.",Disposition of parenteral butorphanol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6105056/),h,3,233176,DB00611,Butorphanol
,19161457,half life of absorption,Absorption of butorphanol after IM administration was very rapid (half life of absorption of 6 min) but systemic availability after IM injection was low (37%).,Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),min,6,235419,DB00611,Butorphanol
,19161457,Terminal half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,0.57,235420,DB00611,Butorphanol
,19161457,Terminal half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,7.7,235421,DB00611,Butorphanol
,19161457,half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,0.57,235422,DB00611,Butorphanol
,19161457,half-life,"Terminal half-life after IV administration was much longer than half-life after IM administration (0.57 h and 7.7 h, respectively).",Pharmacokinetics of butorphanol in horses after intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161457/),h,7.7,235423,DB00611,Butorphanol
,1586025,half-life,"The half-life was calculated to be 1.64 hours via IV administration, whereas SC injection resulted in an elimination half-life of 3.16 hours.",Pharmacokinetics of butorphanol tartrate in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586025/),h,1.64,240270,DB00611,Butorphanol
,1586025,elimination half-life,"The half-life was calculated to be 1.64 hours via IV administration, whereas SC injection resulted in an elimination half-life of 3.16 hours.",Pharmacokinetics of butorphanol tartrate in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586025/),h,3.16,240271,DB00611,Butorphanol
,28541145,Half-life of the terminal slope,Half-life of the terminal slope was 3.41 hours.,Pharmacokinetics of butorphanol tartrate in a long-acting poloxamer 407 gel formulation administered to Hispaniolan Amazon parrots (Amazona ventralis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541145/),h,3.41,243946,DB00611,Butorphanol
,18976284,terminal half-life,The terminal half-life of butorphanol was 2.1 hours and C0 was 33.2 +/- 12.1 ng/mL after IV injection.,Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18976284/),h,2.1,245343,DB00611,Butorphanol
,18976284,C0,The terminal half-life of butorphanol was 2.1 hours and C0 was 33.2 +/- 12.1 ng/mL after IV injection.,Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18976284/),[ng] / [ml],33.2,245344,DB00611,Butorphanol
,18976284,Cmax,"For IM injection, Cmax and Tmax were 20.1 +/- 3.5 ng/mL and 5.9 +/- 2.1 minutes, respectively.",Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18976284/),[ng] / [ml],20.1,245345,DB00611,Butorphanol
,18976284,Tmax,"For IM injection, Cmax and Tmax were 20.1 +/- 3.5 ng/mL and 5.9 +/- 2.1 minutes, respectively.",Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18976284/),min,5.9,245346,DB00611,Butorphanol
,18976284,Bioavailability,Bioavailability was 66.1 +/- 11.9%.,Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18976284/),%,66.1,245347,DB00611,Butorphanol
,22642499,plasma elimination half life (t½),"The harmonic, mean ± SD plasma elimination half life (t½) for alfaxalone was 22.8 ± 5.2 minutes.",Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642499/),min,22.8,258154,DB00611,Butorphanol
,22642499,plasma clearance (Cl(p) ),"The observed mean plasma clearance (Cl(p) ) and volume of distribution (Vd) were 19.9 ± 5.9 mL minute kg(-1) and 0.6 ± 0.2 L kg(-1) , respectively.",Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642499/),[min·ml] / [kg],19.9,258155,DB00611,Butorphanol
,22642499,volume of distribution (Vd),"The observed mean plasma clearance (Cl(p) ) and volume of distribution (Vd) were 19.9 ± 5.9 mL minute kg(-1) and 0.6 ± 0.2 L kg(-1) , respectively.",Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642499/),[l] / [kg],0.6,258156,DB00611,Butorphanol
,22642499,durations,"The mean durations of anaesthesia from induction to first movement and from induction to standing were 18.7 ± 7 and 37.2 ± 4.7 minutes, respectively.",Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642499/),min,18.7,258157,DB00611,Butorphanol
,22642499,durations,"The mean durations of anaesthesia from induction to first movement and from induction to standing were 18.7 ± 7 and 37.2 ± 4.7 minutes, respectively.",Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642499/),min,37.2,258158,DB00611,Butorphanol
,29891212,Heart rate,Heart rate was significantly higher from 20 to 90 minutes after MBM-MK.,Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,20 to 90,266340,DB00611,Butorphanol
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,23,266341,DB00611,Butorphanol
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,11,266342,DB00611,Butorphanol
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,32,266343,DB00611,Butorphanol
,29891212,Tmax,"The Tmax values for midazolam and levomedetomidine (mean ± standard deviation) were approximately halved with coadministration of MK-467, from 23 ± 9 to 11 ± 6 minutes (p = 0.049) for midazolam and from 32 ± 15 to 18 ± 6 minutes for levomedetomidine (p = 0.036), respectively.",Peripheral α2-adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29891212/),min,18,266344,DB00611,Butorphanol
